Literature DB >> 32873569

Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma.

Laia Bassaganyas1, Roser Pinyol1, Roger Esteban-Fabró1, Laura Torrens1, Sara Torrecilla1, Catherine E Willoughby1, Sebastià Franch-Expósito2, Maria Vila-Casadesús3, Itziar Salaverria4,5, Robert Montal1, Vincenzo Mazzaferro6, Jordi Camps2, Daniela Sia7, Josep M Llovet8,7,9.   

Abstract

PURPOSE: Chromosomal instability is a hallmark of cancer that results in broad and focal copy-number alterations (CNAs), two events associated with distinct molecular, immunologic, and clinical features. In hepatocellular carcinoma (HCC), the role of CNAs has not been thoroughly assessed. Thus, we dissected the impact of CNA burdens on HCC molecular and immune features. EXPERIMENTAL
DESIGN: We analyzed SNP array data from 452 paired tumor/adjacent resected HCCs and 25 dysplastic nodules. For each sample, broad and focal CNA burdens were quantified using CNApp, and the resulting broad scores (BS) and focal scores (FS) were correlated with transcriptomic, mutational, and methylation profiles, tumor immune composition, and clinicopathologic data.
RESULTS: HCCs with low broad CNA burdens (defined as BS ≤ 4; 17%) presented high inflammation, active infiltrate signaling, high cytolytic activity, and enrichment of the "HCC immune class" and gene signatures related to antigen presentation. Conversely, tumors with chromosomal instability (high broad CNA loads, BS ≥ 11; 40%), displayed immune-excluded traits and were linked to proliferation, TP53 dysfunction, and DNA repair. Candidate determinants of the low cytotoxicity and immune exclusion features of high-BS tumors included alterations in antigen-presenting machinery (i.e., HLA), widespread hypomethylation, and decreased rates of observed/expected neoantigenic mutations. High FSs were independent of tumor immune features, but were related to proliferation, TP53 dysfunction, and progenitor cell traits.
CONCLUSIONS: HCCs with high chromosomal instability exhibit features of immune exclusion, whereas tumors displaying low burdens of broad CNAs present an immune active profile. These CNA scores can be tested to predict response to immunotherapies. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32873569      PMCID: PMC7710584          DOI: 10.1158/1078-0432.CCR-20-1497

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  52 in total

1.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Authors:  Derek Y Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C LeBlanc; Diana J Donovan; Swan N Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H Ligon; Vesna Najfeld; Scott L Friedman; William R Sellers; Matthew Meyerson; Josep M Llovet
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

Review 2.  Molecular therapies and precision medicine for hepatocellular carcinoma.

Authors:  Josep M Llovet; Robert Montal; Daniela Sia; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2018-10       Impact factor: 66.675

Review 3.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

4.  Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.

Authors:  Sabina Signoretti; Catherine J Wu; Sachet A Shukla; Toni K Choueiri; David A Braun; Yue Hou; Ziad Bakouny; Miriam Ficial; Miriam Sant' Angelo; Juliet Forman; Petra Ross-Macdonald; Ashton C Berger; Opeyemi A Jegede; Liudmilla Elagina; John Steinharter; Maxine Sun; Megan Wind-Rotolo; Jean-Christophe Pignon; Andrew D Cherniack; Lee Lichtenstein; Donna Neuberg; Paul Catalano; Gordon J Freeman; Arlene H Sharpe; David F McDermott; Eliezer M Van Allen
Journal:  Nat Med       Date:  2020-05-29       Impact factor: 53.440

5.  Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.

Authors:  Jan Budczies; Anja Seidel; Petros Christopoulos; Volker Endris; Matthias Kloor; Balázs Győrffy; Barbara Seliger; Peter Schirmacher; Albrecht Stenzinger; Carsten Denkert
Journal:  Oncoimmunology       Date:  2018-10-19       Impact factor: 8.110

6.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

7.  Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.

Authors:  Cédric Coulouarn; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Hepatology       Date:  2008-06       Impact factor: 17.425

8.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Authors:  Kornelius Schulze; Sandrine Imbeaud; Eric Letouzé; Ludmil B Alexandrov; Julien Calderaro; Sandra Rebouissou; Gabrielle Couchy; Clément Meiller; Jayendra Shinde; Frederic Soysouvanh; Anna-Line Calatayud; Roser Pinyol; Laura Pelletier; Charles Balabaud; Alexis Laurent; Jean-Frederic Blanc; Vincenzo Mazzaferro; Fabien Calvo; Augusto Villanueva; Jean-Charles Nault; Paulette Bioulac-Sage; Michael R Stratton; Josep M Llovet; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2015-03-30       Impact factor: 38.330

9.  Inferring tumour purity and stromal and immune cell admixture from expression data.

Authors:  Kosuke Yoshihara; Maria Shahmoradgoli; Emmanuel Martínez; Rahulsimham Vegesna; Hoon Kim; Wandaliz Torres-Garcia; Victor Treviño; Hui Shen; Peter W Laird; Douglas A Levine; Scott L Carter; Gad Getz; Katherine Stemke-Hale; Gordon B Mills; Roel G W Verhaak
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.

Authors:  Alejandro Jiménez-Sánchez; Paulina Cybulska; Katherine LaVigne Mager; Simon Koplev; Oliver Cast; Dominique-Laurent Couturier; Danish Memon; Pier Selenica; Ines Nikolovski; Yousef Mazaheri; Yonina Bykov; Felipe C Geyer; Geoff Macintyre; Lena Morrill Gavarró; Ruben M Drews; Michael B Gill; Anastasios D Papanastasiou; Ramon E Sosa; Robert A Soslow; Tyler Walther; Ronglai Shen; Dennis S Chi; Kay J Park; Travis Hollmann; Jorge S Reis-Filho; Florian Markowetz; Pedro Beltrao; Hebert Alberto Vargas; Dmitriy Zamarin; James D Brenton; Alexandra Snyder; Britta Weigelt; Evis Sala; Martin L Miller
Journal:  Nat Genet       Date:  2020-06-01       Impact factor: 38.330

View more
  16 in total

Review 1.  Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics.

Authors:  Taiji Yamazoe; Taizo Mori; Sachiyo Yoshio; Tatsuya Kanto
Journal:  Glob Health Med       Date:  2020-10-31

2.  A m6A methyltransferase-mediated immune signature determines prognosis, immune landscape and immunotherapy efficacy in patients with lung adenocarcinoma.

Authors:  Mengyuan Lei; Chenghan Luo; Jiayang Zhang; Wenjun Cao; Jian Ge; Min Zhao
Journal:  Cell Oncol (Dordr)       Date:  2022-08-15       Impact factor: 7.051

3.  Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.

Authors:  Carla Montironi; Florian Castet; Philipp K Haber; Roser Pinyol; Miguel Torres-Martin; Laura Torrens; Agavni Mesropian; Huan Wang; Marc Puigvehi; Miho Maeda; Wei Qiang Leow; Elizabeth Harrod; Patricia Taik; Jigjidsuren Chinburen; Erdenebileg Taivanbaatar; Enkhbold Chinbold; Manel Solé Arqués; Michael Donovan; Swan Thung; Jaclyn Neely; Vincenzo Mazzaferro; Jeffrey Anderson; Sasan Roayaie; Myron Schwartz; Augusto Villanueva; Scott L Friedman; Andrew Uzilov; Daniela Sia; Josep M Llovet
Journal:  Gut       Date:  2022-02-23       Impact factor: 31.793

Review 4.  Immunotherapies for hepatocellular carcinoma.

Authors:  Josep M Llovet; Florian Castet; Mathias Heikenwalder; Mala K Maini; Vincenzo Mazzaferro; David J Pinato; Eli Pikarsky; Andrew X Zhu; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2021-11-11       Impact factor: 65.011

Review 5.  Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.

Authors:  Josep M Llovet; Roser Pinyol; Robin K Kelley; Anthony El-Khoueiry; Helen L Reeves; Xin Wei Wang; Gregory J Gores; Augusto Villanueva
Journal:  Nat Cancer       Date:  2022-04-28

6.  Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.

Authors:  Xu Yang; Ying Hu; Keyan Yang; Dongxu Wang; Jianzhen Lin; Junyu Long; Fucun Xie; Jinzhu Mao; Jin Bian; Mei Guan; Jie Pan; Li Huo; Ke Hu; Xiaobo Yang; Yilei Mao; Xinting Sang; Jiao Zhang; Xi Wang; Henghui Zhang; Haitao Zhao
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

7.  Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy.

Authors:  Xiaobo Zheng; Yong Gao; Chune Yu; Guiquan Fan; Pengwu Li; Ming Zhang; Jing Yu; Mingqing Xu
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

8.  Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study.

Authors:  Ioannis Zerdes; Michele Simonetti; Alexios Matikas; Luuk Harbers; Balazs Acs; Ceren Boyaci; Ning Zhang; Dimitrios Salgkamis; Susanne Agartz; Pablo Moreno-Ruiz; Yalai Bai; David L Rimm; Johan Hartman; Artur Mezheyeuski; Jonas Bergh; Nicola Crosetto; Theodoros Foukakis
Journal:  NPJ Breast Cancer       Date:  2021-11-19

9.  Integrated Analysis of MATH-Based Subtypes Reveals a Novel Screening Strategy for Early-Stage Lung Adenocarcinoma.

Authors:  Chang Li; Chen Tian; Yulan Zeng; Jinyan Liang; Qifan Yang; Feifei Gu; Yue Hu; Li Liu
Journal:  Front Cell Dev Biol       Date:  2022-02-08

10.  Inducing immunogenic cell death in immuno-oncological therapies.

Authors:  Dongdong Ti; Xin Yan; Jianshu Wei; Zhiqiang Wu; Yao Wang; Weidong Han
Journal:  Chin J Cancer Res       Date:  2022-02-28       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.